Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors

Cancer Research

Volumn 59, Issue 21, 1999, Pages 5492-5496

  Du, Wei ^a,b   Prendergast, George C ^a,b  

^a DUPONT COMPANY   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAS PROTEIN; RHO FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; CELL CYCLE; CELL DIVISION; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; PLASMIDS; PROTEIN ISOPRENYLATION; RECOMBINANT FUSION PROTEINS; RHOB GTP-BINDING PROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; ZINC;

EID: 0033231190     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Gibbs, J., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
2. Gibbs, J. B., and Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37: 143-166, 1997.
3. Leonard, D. M. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem., 40: 2971-2990, 1997.
4. Sebti, S. M., and Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther., 74: 103-114, 1997.
5. Cox, A. D., and Der, C. J,. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333: F51-71, 1997.
6. Lebowitz, P. F., and Prendergast, G. C. Non-Ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene, 17: 1439-1447, 1998.
7. Prendergast, G. C., and Du, W. Targeting farnesyltransferase: is Ras relevant? Drug Resist. Updates, 2: 81-84, 1999.
8. Casey, P. J., and Seabra, M. C. Protein prenyltransferases. J. Biol. Chem., 271: 5289-5292, 1996.
9. Zhang, F. L., and Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem., 65: 241-269, 1996.
10. Cox, A. D., Hisaka, M. M., Buss, J. E., and Der, C. J., Specific isoprenoid modification is required for function of normal, but not oncogenic. Ras function. Mol. Cell. Biol., 12: 2606-2615, 1992.
11. Lebowitz, P., Casey, P. J., Prendergast, G. C. and Thissen, J. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem., 272: 15591-15594, 1997.
12. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Nati. Acad. Sci. USA, 89: 6403-6407, 1992.
13. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
14. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
15. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
16. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
17. Kohl, N. E., Redner, F., Mosser, S., Guiliani, E. A., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
18. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
19. Manne, V., Yan, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D., Zahler, R., Weinmann, R., Der, C. J., Cox, A. D., Hunt, J. T., Gordon, E. M., Barbacid, M., and Seizinger, B. R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene, 10: 1763-1779, 1995.
20. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
21. Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E., Graham, S., Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
22. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
23. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
24. Du, W., Lebowitz, P., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol., 19: 1831-1840, 1999.
25. Fritz, G., Just, I., and Kaina, B. Rho GTPases are overexpressed in human tumors. Int. J. Cancer, 81: 682-687, 1999.
26. Itoh, K., Yoshioka, K., Akedo, H., Uegata, M., Ishizaki, T., and Narumiya, S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med., 5: 221-225, 1999.
27. Michiels, F., and Collard, J. G. Rho-like GTPases: their role in cell adhesion and invasion. Biochem. Soc. Symp., 65: 125-146, 1999.
28. Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya; S., Hiai, H., and Fukumoto, M. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer, 77: 147-152, 1998.
29. Yoshioka, K., Hakamori, S., and Itoh, K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res., 59: 2004-2010, 1999.
30. Adamson, P., Marshall, C. J., Hall, A., and Tilbrook, P. A. Post-translational modification of p21rho proteins. J. Biol. Chem., 267: 20033-20038, 1992.
31. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol., 15: 6613-6622, 1995.
32. Cook, D. M., Hinkes, M. T., Bernfield, M., and Rauscher, F. J. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene, 13: 1789-1799, 1996.
33. Hawley, R. G., Lieu, F. H., Fong, A. Z., and Hawley, T. S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther., 1: 136-138, 1994.
34. Jiang, W., and Hunter, T. Analysis of cell-cycle profiles in transfected cells using a membrane-targeted GFP. Biotechniques, 24: 349-354, 1998.
35. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
36. Lerner, E. C., Zhang, T. T., Knowles, D. B., Qian, Y. M., Hamilton, A. D., and Sebti, S. M. Inhibition of the prenylation of K-Ras, but not H-or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase-1 inhibitor in human tumor cell lines. Oncogene, 15: 1283-1288, 1997.
37. Rowell, C. A., Kowakzyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
38. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 16: 1467-1473, 1998.
39. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Olivia, I., James, L., Catino J. J., Bishop, W. R., and Pai, J. K. K- and N-ras geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
40. 1 and induces p21 (WAF1/ CIP1/SDI1) in a p53-independent manner. J. Biol. Chem., 272: 27224-27229, 1997.
41. 1 block in p53 wild type tumor cells. J. Biol. Chem., 273: 20243-20251, 1998.
42. 2-M enrichment in A549 cells. Cancer Res., 57: 1846-1850, 1997.
43. Suzuki, N., Urano, J., and Tamanoi, F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA, 95: 15356-15361, 1998.
44. Du, W., Liu, A., and Prendergast, G. C. Activation of the P13′K-AKT pathway masks the proapoptotic effect of farnesyltransferase inhibitors. Cancer Res., 59:4208-4212, 1999.
45. James, G. L., Goldstein, J. L., and Brown, M. S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
46. Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., and Tamanoi, F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA, 90: 2281-2285, 1993.
47. Ito, T., Kawata, S., Tamura, S., Igura, T., Nagase, T., Miyagawa, J. I., Yamazaki, E., Ishiguro, H., and Matasuzawa, Y. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn. J. Cancer Res., 87: 113-116, 1996.
48. 1 integrin receptor. FEBS Lett., 363: 78-80, 1995.
49. Burridge, K., and Chrzanowska-Wodnicka, M. Focal adhesions, contractility, and signaling. Annu. Rev. Cell. Dev. Biol., 12: 463-518, 1996.
50. Hotchin, N. A., and Hall, A. The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases. J. Cell Biol., 131: 1857-1865, 1995.
51. Hotchin, N. A., and Hall, A. Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases. Cancer Surv., 27: 311-322, 1996.
52. Udagawa, T., and McIntyre, B. W. ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth. J. Biol. Chem., 271: 12542-12548, 1996.